AMPH Earnings Date: Nov 5, 2026 (Estimated) — Amphastar Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is AMPH's next earnings date?
Amphastar Pharmaceuticals, Inc. (AMPH) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.86 on revenue of $197.5M.
How did AMPH do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Amphastar Pharmaceuticals, Inc. posted EPS of $0.91 versus the $0.62 estimate, a beat of 46.8%. Revenue was $183.9M against a $179.9M estimate. The stock's 1-day post-earnings move was +4.9%.
How much does AMPH stock move after earnings?
AMPH beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.1% (up or down) in the day after earnings.
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.62 | 0.91 | +46.77% | $183.9M | ✅ Beat | +4.90% | +1.87% | +17.01% |
| 2026-05-07 | Q1 2026 | 0.69 | 0.42 | -39.13% | $171.2M | ❌ Miss | -20.93% | -28.01% | -19.31% |
| 2026-02-26 | Q4 2025 | 0.91 | 0.73 | -19.78% | $183.1M | ❌ Miss | -23.63% | -22.84% | -28.24% |
| 2025-11-06 | Q3 2025 | 0.79 | 0.93 | +17.72% | $191.8M | ✅ Beat | -0.83% | +8.83% | +7.35% |
| 2025-08-07 | Q2 2025 | 0.70 | 0.85 | +21.43% | $174.4M | ✅ Beat | +10.13% | +39.73% | +35.34% |
| 2025-02-27 | Q4 2024 | 0.94 | 0.92 | -2.13% | $186.5M | ❌ Miss | -9.72% | -10.07% | -9.72% |
| 2024-11-06 | Q3 2024 | 0.99 | 0.96 | -3.03% | $191.2M | ❌ Miss | -13.69% | -14.83% | -17.98% |
| 2024-08-07 | Q2 2024 | 0.77 | 0.94 | +22.08% | $182.4M | ✅ Beat | +13.29% | +9.13% | +16.69% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $183.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Other Products | 36.0% | $66.2M | +24.7% | — | — | $53.1M | $64.1M |
| BAQSIMI | 24.7% | $45.5M | -2.5% | — | — | $46.7M | $53.6M |
| Primatene MIST | 11.4% | $21.0M | -8.2% | — | — | $22.9M | $28.8M |
| Epinephrine | 8.6% | $15.9M | -2.0% | — | — | $16.2M | $18.8M |
| Lidocaine | 8.2% | $15.0M | +0.3% | — | — | $15.0M | $12.9M |
| Glucagon | 6.5% | $11.9M | -42.2% | — | — | $20.6M | $13.6M |
| Ipratropium Bromide Member | 4.6% | $8.4M | — | — | — | — | — |
By region
Q2 FY26 · $183.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| United States | 93.7% | $172.3M | — | — | — | — | — |
| France | 3.8% | $7.0M | — | — | — | — | — |
| China | 2.5% | $4.6M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.